PURPOSE: Microarray studies indicate medulloblastoma comprises distinct molecular disease subgroups, which offer potential for improved clinical management. EXPERIMENTAL DESIGN: Minimal mRNA expression signatures diagnostic for the Wnt/Wingless (WNT) and Sonic Hedgehog (SHH) subgroups were developed, validated, and used to assign subgroup affiliation in 173 tumors from four independent cohorts, alongside a systematic investigation of subgroup clinical and molecular characteristics. RESULTS: WNT tumors [12% (21/173)] were diagnosed >5 years of age (peak, 10 years), displayed classic histology, CTNNB1 mutation (19/20), and associated chromosome 6 loss, and have previously been associated with favorable prognosis. SHH cases [24% (42/173)] predominated in infants (<3 years) and showed an age-dependent relationship to desmoplastic/nodular pathology; all infant desmoplastic/nodular cases (previously associated with a good outcome) were SHH-positive, but these relationships broke down in noninfants. PTCH1 mutations were common [34% (11/32)], but PTCH1 exon1c hypermethylation, chromosome 9q and REN (KCTD11) genetic loss were not SHH associated, and SMO or SUFU mutation, PTCH1 exon1a or SUFU hypermethylation did not play a role, indicating novel activating mechanisms in the majority of SHH cases. SHH tumors were associated with an absence of COL1A2 methylation. WNT/SHH-independent medulloblastomas [64% (110/173)] showed all histologies, peaked at 3 and 6 years, and were exclusively associated with chromosome 17p loss. CONCLUSIONS: Medulloblastoma subgroups are characterized by distinct genomic, epigenomic and clinicopathologic features, and clinical outcomes. Validated array-independent gene expression assays for the rapid assessment of subgroup affiliation in small biopsies provide a basis for their routine clinical application, in strategies including molecular disease-risk stratification and delivery of targeted therapeutics.
PURPOSE: Microarray studies indicate medulloblastoma comprises distinct molecular disease subgroups, which offer potential for improved clinical management. EXPERIMENTAL DESIGN: Minimal mRNA expression signatures diagnostic for the Wnt/Wingless (WNT) and Sonic Hedgehog (SHH) subgroups were developed, validated, and used to assign subgroup affiliation in 173 tumors from four independent cohorts, alongside a systematic investigation of subgroup clinical and molecular characteristics. RESULTS: WNT tumors [12% (21/173)] were diagnosed >5 years of age (peak, 10 years), displayed classic histology, CTNNB1 mutation (19/20), and associated chromosome 6 loss, and have previously been associated with favorable prognosis. SHH cases [24% (42/173)] predominated in infants (<3 years) and showed an age-dependent relationship to desmoplastic/nodular pathology; all infant desmoplastic/nodular cases (previously associated with a good outcome) were SHH-positive, but these relationships broke down in noninfants. PTCH1 mutations were common [34% (11/32)], but PTCH1 exon1c hypermethylation, chromosome 9q and REN (KCTD11) genetic loss were not SHH associated, and SMO or SUFU mutation, PTCH1 exon1a or SUFU hypermethylation did not play a role, indicating novel activating mechanisms in the majority of SHH cases. SHH tumors were associated with an absence of COL1A2 methylation. WNT/SHH-independent medulloblastomas [64% (110/173)] showed all histologies, peaked at 3 and 6 years, and were exclusively associated with chromosome 17p loss. CONCLUSIONS: Medulloblastoma subgroups are characterized by distinct genomic, epigenomic and clinicopathologic features, and clinical outcomes. Validated array-independent gene expression assays for the rapid assessment of subgroup affiliation in small biopsies provide a basis for their routine clinical application, in strategies including molecular disease-risk stratification and delivery of targeted therapeutics.
Authors: Steven C Clifford; Meryl E Lusher; Janet C Lindsey; Jacqueline A Langdon; Richard J Gilbertson; Debbie Straughton; David W Ellison Journal: Cell Cycle Date: 2006-11-15 Impact factor: 4.534
Authors: Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson Journal: Lancet Oncol Date: 2006-10 Impact factor: 41.316
Authors: Charles S McManamy; Jane Pears; Claire L Weston; Zoltan Hanzely; James W Ironside; Roger E Taylor; Richard G Grundy; Steven C Clifford; David W Ellison Journal: Brain Pathol Date: 2007-04 Impact factor: 6.508
Authors: Jennifer A Anderton; Janet C Lindsey; Meryl E Lusher; Richard J Gilbertson; Simon Bailey; David W Ellison; Steven C Clifford Journal: Neuro Oncol Date: 2008-07-29 Impact factor: 12.300
Authors: Marcel Kool; Jan Koster; Jens Bunt; Nancy E Hasselt; Arjan Lakeman; Peter van Sluis; Dirk Troost; Netteke Schouten-van Meeteren; Huib N Caron; Jacqueline Cloos; Alan Mrsić; Bauke Ylstra; Wieslawa Grajkowska; Wolfgang Hartmann; Torsten Pietsch; David Ellison; Steven C Clifford; Rogier Versteeg Journal: PLoS One Date: 2008-08-28 Impact factor: 3.240
Authors: André O von Bueren; Joachim Gerss; Christian Hagel; Haoyang Cai; Marc Remke; Martin Hasselblatt; Burt G Feuerstein; Sarah Pernet; Olivier Delattre; Andrey Korshunov; Stefan Rutkowski; Stefan M Pfister; Michael Baudis Journal: J Neurooncol Date: 2012-07-07 Impact factor: 4.130
Authors: Edward C Schwalbe; Daniel Williamson; Janet C Lindsey; Dolores Hamilton; Sarra L Ryan; Hisham Megahed; Miklós Garami; Peter Hauser; Bożena Dembowska-Baginska; Danuta Perek; Paul A Northcott; Michael D Taylor; Roger E Taylor; David W Ellison; Simon Bailey; Steven C Clifford Journal: Acta Neuropathol Date: 2013-01-05 Impact factor: 17.088
Authors: Pete Taylor; Jason Fangusaro; Veena Rajaram; Stewart Goldman; Irene B Helenowski; Tobey MacDonald; Martin Hasselblatt; Lars Riedemann; Alvaro Laureano; Laurence Cooper; Vidya Gopalakrishnan Journal: Mol Cancer Ther Date: 2012-07-30 Impact factor: 6.261
Authors: Stefan Blüml; Ashley S Margol; Richard Sposto; Rebekah J Kennedy; Nathan J Robison; Marzieh Vali; Long T Hung; Sakunthala Muthugounder; Jonathan L Finlay; Anat Erdreich-Epstein; Floyd H Gilles; Alexander R Judkins; Mark D Krieger; Girish Dhall; Marvin D Nelson; Shahab Asgharzadeh Journal: Neuro Oncol Date: 2015-08-08 Impact factor: 12.300